MEDIX, God. 26 Br. 144/145  •  Pregledni članak  •  Baromedicina HR ENG

Hiperbarična oksigenacija i COVID-19Hyperbaric oxygen therapy and COVID-19

Mladen Merćep

U oko 9% hospitaliziranih bolesnika s COVID-om 19 dolazi do razvoja akutnoga respiratornoga distresnoga sindroma (ARDS) koji zahtijeva mehaničku ventilaciju pluća, pri čemu je smrtnost takvih bolesnika oko 66%. Zato nam je potrebna učinkovitija metoda korekcije tkivne hipoksije. Zbog povoljnog učinka HBOT-a, na malome broju bolesnika oboljelih od teškog oblika Španjolske gripe te rezultatima na malome broju bolesnika s COVID-om 19 liječenih HBOT-om, razumno je ispitati mogućnost primjene HBOT-a u liječenju tih bolesnika. U svijetu se učinak HBOT-a na COVID-19 trenutno ispituje u 8 kliničkih istraživanja.

Ključne riječi:
COVID-19; SARS-Cov-2; HBOT; hiperbarična oksigenacija; ARDS (akutni respiratorni distresni sindrom)

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 26 Br. 144/145

About 9% of hospitalized COVID-19 patients develop acute respiratory distress syndrome (ARDS), which requires mechanical ventilation and has a mortality of about 66%. The current treatment strategy for correcting tissue hypoxia is not efficient enough. Following a favourable therapeutic effect in a small sample of patients suffering from severe Spanish flu and its efficacy in a small sample of COVID-19 patients, it is reasonable to explore the use of HBOT in the treatment of these patients. Currently, eight clinical studies are examining the effect of HBOT on COVID-19.

Key words:
ARDS (acute respiratory distress syndrome); COVID-19; HBOT (hyperbaric oxygen therapy); SARS-Cov-2